From the National COVID-19 Clinical Evidence Taskforce 

    • The Taskforce has published a decision tool on drug treatments for at risk adults with COVID-19 who do not require oxygen.  It should be used in conjunction with the recently published risk classification tool.  See also the drug treatment flowcharts.
    • A statement has been added to the remark of the sotrovimab 'for use' recommendations highlighting in vitro data which suggests a potential reduction in efficacy of sotrovimab against the BA.2 subvariant. 
    • The Disease-Modifying Treatments and Chemoprophylaxis Panel has reviewed the evidence for monoclonal antibody bebtelovimab and immunomodulator CD24Fc, and recommended that they should only be used in research settings with appropriate ethical approval.
    • In awareness of recent in vitro data suggesting a potential reduction in effectiveness of sotrovimab against Omicron BA.2, the Taskforce has updated the conditional and consensus sotrovimab recommendations. The remarks have also been updated for the paediatric and pregnancy sotrovimab recommendations, and will be reviewed at the next panel meetings.
    • Topics under review​
      • Anakinra
      • Baricitinib
      • Colchicine
      • Dexamethasone
      • Ivermectin
      • Regdanvimab
      • Sarilumab
      • Sotrovimab
      • Tocilizumab
      • Prone positioning
      • Timing of surgery following COVID-19 infection
      • Care of people with post-COVID-19
    • 17 clinical flowcharts have been developed by the Taskforce to cover:
      • Risk classification tool for adults with mild COVID-1
      • Drug treatment decision aid for at risk adults with COVID-19 who do not require oxygen NEW
      • Drug treatments for adults with COVID-19 UPDATED
      • Drug treatments for children and adolescents
      • Drug treatments for pregnancy and breastfeeding
      • Pathways to care for adults with COVID-19 
      • Pathways to care for children and adolescents with COVID-19 
      • Management of adults with mild COVID-19 
      • Management of adults with moderate to severe COVID-19
      • Management of adults with severe to critical COVID-19
      • Respiratory support for adults with severe to critical COVID-19
      • Management of people with COVID-19 who are older and living with frailty and/or cognitive impairment 
      • Management of people with COVID-19 who are receiving palliative care 
      • Care of people with post-COVID-19
      • Preparedness for CPR during the COVID-19 pandemic
      • CPR for adults with COVID-19 in healthcare settings
      • Basic life support for adults in the community during the pandemic


    COVID-19 Research Review First Edition

    • COVID-19 Research Review is an Australian publication bringing you some of the most important research from around the world. The Review is a summary of significant new papers, plus local commentary on why they are important and how they can potentially affect practice.  Subscribe to Research Review updates across 40+ clinical areas here.

    Remember to check EKS COVID-19 Updates and Epworth's IPAC intranet page.

    Published on 26/08/2021 00:00 • Show all news
    Log in to your account:

    Students - must register here to borrow books.  Remember to confirm your registration in order to checkout.

    Online resources are available via your university or Epworth computers.



    Don't have an account? Register here.


    Hosted by Prosentient